Clinical observations with doses of 4, 6, 7.4, and 9.3 GBq of 177Lu-PSMA-617 repeated every 2 month
Latest Information Update: 28 Mar 2019
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Mar 2019 New trial record